Cardiac (CMRI) Assessment of Acromegaly

• Status: Completed
• Trial end date: 2019-02-28
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the investigators will evaluate the cardiac structure and function, focusing on the myocardial water content and interstitial fibrosis, in patients with active acromegaly in comparison with 1) healthy volunteers, 2) the same acromegalic patients that have received efficient therapy.

The investigators hypothesize that the myocardial water content in acromegaly is increased as these patients present with sodium and water retention and that this myocardial water infiltration will improve with efficient treatment of the disease. They will thus assess using CMRI, this parameter by measuring the myocardial transverse relaxation time (T2), reflecting water content in the myocardium.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: Pfizer

Criteria

Inclusion Criteria:

• Active acromegaly as defined by the usual diagnostic criteria (de novo patients or patients uncontrolled by previous treatments).

• Healthy volunteers matched for age, sex and BMI with the patients of the group 1

Exclusion Criteria:

• History of coronary heart disease (acute or chronic myocardial ischemia)

• Acute or chronic renal failure (creatinin clearance 30 mL/min/l,73m2)

• Contraindication of MRI

• Hypersensitivity to gadolinium

• Pregnancy